Over the past year, we’ve witnessed the biotech bull market expand, deflate and expand again—specifically in relation to RNA-based therapeutic companies. The innovators in the space have increased and decreased their investment levels in the technology, leaving investors, the media, and some in the scientific community wondering which way the pendulum will ultimately swing. In … Continue reading “RNA Therapeutics Are Here to Stay”
Author: Kleanthis Xanthopoulos
RNA Therapeutics Are Coming of Age
RNA therapeutics are new, innovative high-impact medicines. The combined efforts of pioneering biotechnology companies, pharmaceutical and academic institutions have helped these treatments, which act on ribonucleic acids in the cell, to evolve and come of age. For those unfamiliar, these medicines are designed to target RNA and can ultimately affect many cellular components. They can … Continue reading “RNA Therapeutics Are Coming of Age”
Me-Too Drugs
[Editor’s Note: We asked selected Xconomists a series of questions designed to zero in on the big issues of the year, including “What would you be willing to throw a punch over?”] The FDA is the easy target for those of us who are in drug development. But what I am most mad about is … Continue reading “Me-Too Drugs”
Some Prognostications on Biotechnology in 2011
After consulting with the Oracle at the Temple of Apollo at Delphi, here are a few of the trends I was told to watch for in 2011… Two revolutionizing pharmaceutical frontiers are on the horizon—RNA therapeutics and stem cell therapies: —RNA therapeutics will become a big reality in 2011. Mipomersen, a LDL lowering drug from … Continue reading “Some Prognostications on Biotechnology in 2011”